ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 227 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,767,401 | +76.6% | 1,044,501 | +103.0% | 0.11% | +84.5% |
| Q2 2023 | $12,324,047 | +203.3% | 514,574 | +138.3% | 0.06% | +190.0% |
| Q1 2023 | $4,063,840 | -49.5% | 215,932 | -57.2% | 0.02% | -55.6% |
| Q4 2022 | $8,041,256 | -30.2% | 505,104 | -28.3% | 0.04% | -27.4% |
| Q3 2022 | $11,527,000 | -21.5% | 704,565 | -32.4% | 0.06% | -18.4% |
| Q2 2022 | $14,685,000 | +42.8% | 1,042,255 | +145.4% | 0.08% | +31.0% |
| Q1 2022 | $10,285,000 | +35.2% | 424,661 | +30.3% | 0.06% | +38.1% |
| Q4 2021 | $7,607,000 | -40.5% | 325,913 | -57.7% | 0.04% | -48.8% |
| Q3 2021 | $12,784,000 | -12.7% | 769,672 | +28.2% | 0.08% | -19.6% |
| Q2 2021 | $14,645,000 | -11.2% | 600,432 | -6.1% | 0.10% | -15.0% |
| Q1 2021 | $16,496,000 | +339.2% | 639,364 | +512.7% | 0.12% | +84.6% |
| Q3 2019 | $3,756,000 | +1055.7% | 104,352 | +758.2% | 0.06% | +622.2% |
| Q2 2019 | $325,000 | -64.2% | 12,160 | -64.0% | 0.01% | -66.7% |
| Q1 2019 | $907,000 | – | 33,778 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |